Research Analysts’ Recent Ratings Updates for MeiraGTx (MGTX)

Several brokerages have updated their recommendations and price targets on shares of MeiraGTx (NASDAQ: MGTX) in the last few weeks:

• 3/27/2026 – MeiraGTx had its price target lowered by Piper Sandler from $30.00 to $26.00. They now have an “overweight” rating on the stock.
• 3/27/2026 – MeiraGTx had its price target raised by Bank of America Corporation from $14.00 to $16.00. They now have a “buy” rating on the stock.
• 3/27/2026 – MeiraGTx had its “buy” rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
• 3/9/2026 – MeiraGTx was upgraded by Zacks Research from “strong sell” to “hold”.
• 1/30/2026 – MeiraGTx was downgraded by Zacks Research from “hold” to “strong sell”.

Insiders Place Their Bets

In other news, CEO Alexandria Forbes sold 62,000 shares of the stock in a transaction on Tuesday, March 24th. The stock was sold at an average price of $7.41, for a total transaction of $459,420.00. Following the sale, the chief executive officer directly owned 1,449,695 shares of the company’s stock, valued at approximately $10,742,239.95. This represents a 4.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.50% of the stock is owned by corporate insiders.

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.